2018 Study: Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success in Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancer - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 7, 2018--The “Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers” report has been added to ResearchAndMarkets.com’s offering.
The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.
The report includes:An overview of both the problems and phenomenal opportunities with cell therapy and immunotherapy in general. While there are several biological and also commercial issues still to more completely resolve, perhaps the largest challenges are scalability and compatibility. Most developers begin by creating cell therapies for smaller groups of individuals, and then when they see real promise, the issue of scalability is addressed Detailed description about Adoptive Cell Therapy (ACT), how it targets the somatic mutations by infusion of autologous or redirected tumor-specific T-cells and its impact on the treatment of several metastasized malignancies A brief examination of the patent landscape Insight into the structure and function of T lymphocytes, identification of the different types of T lymphocytes as well as identifying the T Cell growth factor Coverage of a number of clinical trials being conducted to investigate the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and investigate their use Evaluation of methods to improve TIL yield and tumor reactivity e.g. blockage of programmed cell death 1 (PD-1) and the effect of an agonistic 4-1BB antibody on TIL growth
Key Topics Covered
1. Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated GenesKey Findings Tumor-Infiltrating Lymphocytes (TILs): A New and Exciting Era in Cancer Treatments Adoptive Cell Transfer (ACT) and Therapeutic TILs Ground-Breaking Management of Advanced Metastatic Breast Cancer Successful Advances in TILs Therapies for Cholangiocarcinoma Hope for Immunotherapy Treatments of Gastrointestinal Cancers Limitations of ACT and Therapeutic TILs Overcoming the Limitations of ACT and Therapeutic TILs Expanding Clinical Trial Portfolio Complexities of the TILs Patent Landscape What’s Next for TILs? Outlook and Implications
3. A Note from the Editor
4. Analyst Credentials
For more information about this report visit https://www.researchandmarkets.com/research/k7twbl/2018_study?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180807005904/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/07/2018 04:11 PM/DISC: 08/07/2018 04:11 PM